FBR Capital analyst Christopher James added Corcept to the Alpha Generator list saying the company is well positioned near-term following recent investor meetings based on expectations the business will continue to grow in 2016, Corcept's oncology program has begun to take off with the addition of several exciting investigator sponsored trials in triple-negative breast cancer and castration resistant prostate cancer, and views CORT118335 in non-alcoholic fatty liver disease as a highly attractive potential blockbuster for the company. James rates Corcept an Outperform with a $12 price target on shares.